Glaxosmithkline Pharmaceuticals Ltd News

GlaxoSmithKline Pharma Q3 profit up 29 pc at Rs 296 cr

GlaxoSmithKline Pharmaceuticals on Monday posted 29 per cent increase in consolidated profit after tax at Rs 296 crore for the third quarter ended December 31, 2025. The drugmaker reported a profit after tax of Rs 230 crore for the October-December period of last fiscal. Revenue from operations rose to Rs 1,041 crore from Rs 949 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals Ltd said in a regulatory filing. The company said its competitive performance comes against the backdrop of the broader macro environment and efforts to mitigate internal supply challenges. The implementation of the new Labour Codes did not have a material impact on the company, it added. Shares of the company on Monday settled 1.01 per cent up at Rs 2,511 apiece on BSE.

GSK Pharma shares fall 3% as revenue misses expectations; Q2 breakdown here

GSK Pharma shares fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current financial year

Stocks to Watch today, Nov 7: Bharti Airtel, LIC, Lupin, Bajaj Housing

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today

GSK Pharma gains depend on new launches, traction in base business

The Q1 was impacted by sluggish show of the base business and supply disruption, resulting in brokerages cutting their earnings estimates

GSK enters into oncology segment; launches therapies for gynae cancers

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. "These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women's cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India," GSK India MD Bhushan Akshikar said in a statement. Gynaecological cancers are among the most common cancers in women in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78 per cent and 69 per cent, respectively. Endometrial cancer is a malignancy arising out of the endometrium, the inner lining of the uterus. Nearly a fourth of endometrial cancer patients in India are at an advanced stage where chemotherapy remains a standa